Wyoming Drug Utilization Review (WY-DUR)

School of Pharmacy | College of Health Sciences

News

Preferred Drug List (PDL)

The Wyoming Medicaid Preferred Drug List (PDL) including step utilization for anti-depressant medications and prior authorization information is available at the Wyoming EqualityCare Pharmacy Provider website. To view the current PDL, please visit www.wymedicaid.org.

A draft of the 2020 PDL can be found at the link below. Please note that this is a draft and additional changes may be made.

2020 PDL Draft

Public Comment at Meetings:

A new policy for public comment at meetings is effective December 2, 2012.

PhRMA Guidelines and PhRMA Comment Request Form (updated November 5, 2015)
Public Guidelines and Public Comment Request Form (updated November 5, 2015)

Proposed Criteria

The following prior authorization criteria were approved at the May 8, 2019 P & T Committee meeting.

The Adult ADHD PA form will be updated to include a check box for developmentally/intellectually disabled and a free form area for history of symptoms in other environments.

The time for antidepressant cross tapering will be increased to 90 days.

Bijuva will be limited to indication. Motegrity and Apadaz will be referred to the Department of Health for cost analysis and PDL placement.

Savella will be limited to a maximum of 200 mg per day.

Comments may be sent by email to alewis13@uwyo.edu or by mail to: Wyoming Drug Utilization Review Board, Dept. 3375, 1000 E. University Avenue, Laramie, WY 82071. Comments should be received prior to July 31, 2019.